Background：Tremelimumab CP-675,206; previously, ticilimumab is a fully human IgG2 monoclonal antibody and has a half-life of 22 days, which was generated in a XenoMouse murine system, that has a subnanomolar affinity for binding to human cytotoxic T lymphocyte-associated antigen 4 CTLA-4 for treatment of patients with advanced cancers. Treatment with an anti-CTLA4 mAb prevents normal downregulation of T cells and prolongs T cell activation, thereby enhancing immune function. Generated at Abgenix Fremont, CA using xenomice by Pfizer, Inc. New York, tremelimumab has been undergoing human trials for the treatment of malignant melanoma. Additionally, tremelimumab is under investigation for the treatment of Mesothelioma, Liver Cancer, Liver Neoplasms, Liver Cell Caricinoma, and HepatoCellular Carcinoma and it has been investigated in Part C: Malignant Mesothelioma and Part A and B: Advanced Solid Malignancies. Recently, it has been announced by AstraZeneca and MedImmune that tremelimumab as monotherapy does not improve survival and the primary end point is not reached D4880C00003; NCT01843374. Further data regarding DETERMINE was presented at ASCO 2016, detailing that 571 patients were enrolled and that 81% had died throughout the duration of the study. There was no statistically significant difference between treated patients and placebo patients, and side effects such as diarrhoea, loss of appetite and development of rashes were seen at higher rates in treated patients than in placebo treatments. This indicates a need for further research into the use of tremelimumab as a monotherapy as well as use in combination therapy to potentially achieve better clinical outcomes.
Alternative Names：Ticilimumab, CP-675, CP-675, 206, CP-675206 clone 11.2.1,
